Sort
10,766 grants matching “checkpoint inhibitor”
Cancer-associated fibroblasts promote thyroid cancer malignancy through Wnt signaling
$54,538Matthew A Loberg · Vanderbilt University · F30 · FY2025 · CA
Comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells
$54,538Lillian Xu · Johns Hopkins University · F30 · FY2025 · CA
Dissecting innate immune mechanisms of resistance to checkpoint blockade therapy in bladder cancer
$54,538Michelle Alyssa Tran · Icahn School Of Medicine At Mount Sinai · F30 · FY2025 · CA
Neoantigen-specific T cells in a novel cutaneous squamous cell carcinoma model
$54,538Anngela Christina Adams · University Of Arizona · F30 · FY2025 · CA
Contribution of PAG to Immune Synapse Organization and PD-1 Function
$54,538Emily Kathryn Moore · Columbia University Health Sciences · F30 · FY2025 · CA
Host and microbe-dependent mechanisms of enhanced autoimmune susceptibility driven by checkpoint inhibitors
$54,538Vanessa Salazar · Cleveland Clinic Lerner Com-Cwru · F31 · FY2025 · AI
Thymic PD-1 blockade mediates the anti-tumor immune response in pediatric high-grade glioma
$54,538Connor Patrick Francis · University Of Florida · F30 · FY2025 · CA
Activating Low-Affinity T Cells to Prevent Relapse in Acute Lymphoblastic Leukemia
$54,538Qianyun Luo · University Of Minnesota · F30 · FY2025 · CA
Targeting amyloid beta for myeloid reprogramming in brain metastasis
$54,538Nicole Marie Eskow · New York University School Of Medicine · F30 · FY2025 · CA
Effects of entinostat and neoantigen vaccination on bladder cancer
$54,538Wolfgang Beckabir · Univ Of North Carolina Chapel Hill · F30 · FY2025 · CA
Investigating Immunosuppression in Beta-catenin-mutated Hepatocellular Carcinoma for Improved Precision Medicine Therapeutics
$54,538Brandon Lehrich · University Of Pittsburgh At Pittsburgh · F30 · FY2025 · CA
Alternate splicing as a source of shared neoantigens in a non-small cell lung cancer
$54,538Ryan Englander · University Of Connecticut Sch Of Med/Dnt · F30 · FY2025 · CA
Combining Radiation, Allogeneic Natural Killer Immunotherapy, and PD-L1 blockade in Dogs with Naturally-Occurring Melanoma
$54,538Aryana Razmara · University Of California At Davis · F30 · FY2025 · CA
MODULATION OF HOST CELL APOPTOTIC RESPONSES BY HPVE7
$54,525Harvard University (Medical School) · R01 · FY2002 · CA
Novel roles for the DNA damage response kinase CHK1 in TCR/ITAM signaling
$54,469Carrie L. Lucas · Yale University · R01 · FY2019 · AI
Regulation of mitotic Aur-A-kinase in checkpoint arrest
$54,352Harvard University (Medical School) · F32 · FY2004 · GM
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$54,324Periasamy Selvaraj · Emory University · R01 · FY2020 · CA
Cancer Immunology
$54,277Drew M. Pardoll · Johns Hopkins University · P30 · FY2022 · CA
Cancer Immunology
$54,277Drew M. Pardoll · Johns Hopkins University · P30 · FY2023 · CA
Cancer Immunology
$54,277Drew M. Pardoll · Johns Hopkins University · P30 · FY2024 · CA
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma
$54,000Maryam Rahman · University Of Florida · K08 · FY2021 · NS
CD8+ T CELL REPROGRAMMING TO BOOST ANTIVIRAL POTENTIAL AGAINST CHRONIC INFECTION
$54,000Federico Perdomo · Pontificia Universidad Javeriana · R03 · FY2024 · AI
CD8+ T CELL REPROGRAMMING TO BOOST ANTIVIRAL POTENTIAL AGAINST CHRONIC INFECTION
$54,000Federico Perdomo · Pontificia Universidad Javeriana · R03 · FY2025 · AI
PD-L1 inhibition promotes type I interferon responses, enhancing chemotherapy-induced cytotoxicity in cancer cells
$53,996Hyeonjoo Cheon · Cleveland Clinic Lerner Com-Cwru · R21 · FY2022 · CA
The Oncogenic functions of YAP/TAZ in Renal Cell Carcinoma
$53,974Alec Thomas McIntosh · Georgetown University · F30 · FY2024 · CA